Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 12/20 | 0.63 |
| ▸ | MMP3 | P08254 | 12/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | USP5 | P45974 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6590247 | 0.89 | MMP2 (0.58) | MMP2MMP3ALDH1A1PKMUSP5 | |
| SCHEMBL6585805 | 0.87 | MMP2 (0.57) | MMP2MMP3ALDH1A1PKMUSP5 | |
| SCHEMBL6590225 | 0.85 | MMP2 (0.63) | MMP2MMP3ALDH1A1PKMUSP5 | |
| SCHEMBL6587473 | 0.77 | MMP2 (0.58) | MMP2MMP3ALDH1A1PKMUSP5 | |
| SCHEMBL6587433 | 0.77 | MMP3 (1.00) | MMP2MMP3ALDH1A1PKMUSP5 | |
| SCHEMBL6586571 | 0.74 | MMP3 (0.95) | MMP2MMP3ALDH1A1PKMUSP5 | |
| SCHEMBL6590060 | 0.73 | MMP3 (0.73) | MMP2MMP3ALDH1A1PKMUSP5 | |
| SCHEMBL6586274 | 0.73 | MMP2 (0.55) | MMP2MMP3KDM4E | |
| SCHEMBL19989648 | 0.72 | SLC6A2 (0.54) | MMP2MMP3KDM4E | |
| SCHEMBL6584277 | 0.72 | MMP2 (0.58) | MMP2MMP3ALDH1A1PKMUSP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1036062-B1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS | PFIZER LTD (GB) | 2004-01-02 | — | — | EP | disclosed |
| US-6495568-B1 | TREATMENT OF TISSUE ULCERATION, WOUND REPAIR AND SKIN DISEASES | WARNER-LAMBERT COMPANY | 2002-12-17 | — | — | US | disclosed |